Comprehensive analysis supports SERMs for cutting breast cancer

April 30, 2013
Comprehensive analysis supports SERMs for cutting breast cancer
Treatment with selective estrogen receptor modulators is associated with a significant reduction in the incidence of breast cancer, especially for the first five years after treatment, according to research described as the first comprehensive analysis, published online April 30 in The Lancet.

(HealthDay)—Treatment with selective estrogen receptor modulators (SERMs) is associated with a significant reduction in the incidence of breast cancer, especially for the first five years after treatment, according to research described as the first comprehensive analysis, published online April 30 in The Lancet.

Jack Cuzick, Ph.D., from the Queen Mary University of London, and colleagues conducted a meta-analysis using data from nine to examine the effectiveness of SERMs on the incidence of breast cancer. Data were analyzed for 83,399 women who were followed for a mean of 65 months for a total of 306,617 women-years of follow-up.

The researchers found that there was a significant, 38 percent reduction overall in the incidence of breast cancer, and that within the first 10 years of follow-up, 42 women needed to be treated to prevent one breast cancer event. In the first five years of follow-up, the reduction was larger than in years five to 10 (hazard ratio, 0.58), but there was no heterogeneity between time periods. With all SERMS, the likelihood of thromboembolic events was significantly increased (odds ratio [OR], 1.73). There was a significant reduction in vertebral fractures (OR, 0.66), while the reduction for non- was smaller, but still significant (OR, 0.93).

"For all SERMs, incidence of invasive estrogen-positive was reduced both during treatment and for at least five years after completion," the authors write. "Similar to other , careful consideration of risks and benefits is needed to identify women who are most likely to benefit from these drugs."

One author disclosed to AstraZeneca; two authors disclosed ties to Eli Lilly.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

CDC: breast cancer mortality higher in black women

November 15, 2012

(HealthDay)—With earlier detection and better treatment, the mortality rate from breast cancer has fallen over the last two decades; black women, however, still die from the disease at a disproportionately higher rate than ...

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.